Sotwe logo Sotwe logo

Top Tweets for #APCCC25

urotoday's profile image
UroToday.com Verified account @urotoday
What can MRI contribute in biochemical recurrence? Presentation by Hebert Vargas, MD @nyulangone. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/JbRfmDKSYP @APCCC_Lugano #APCCC25
urotoday's tweet photo. What can MRI contribute in biochemical recurrence? Presentation by Hebert Vargas, MD @nyulangone. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/JbRfmDKSYP @APCCC_Lugano #APCCC25 https://t.co/VrdAuuGnYh
8
5
3
2
839
Uromigos's profile image
Uromigos Verified account @Uromigos
@TylerSbrt joins us to discuss the #APCCC25 Diagnostics conference live from Lugano! We also discuss our favorite scenic runs... Photo from Tyler below. Any guesses where? https://t.co/WNNnqCXLoo
Uromigos's tweet photo. @TylerSbrt joins us to discuss the #APCCC25 Diagnostics conference live from Lugano! We also discuss our favorite scenic runs... Photo from Tyler below. Any guesses where? https://t.co/WNNnqCXLoo https://t.co/qDplAJxElO
1
11
5
0
3K
urotoday's profile image
UroToday.com Verified account @urotoday
Genomic classifiers at the time of biochemical recurrence. Presented by @dr_coops @UCSFCancer. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/bIDablDss8 @APCCC_Lugano #APCCC25
urotoday's tweet photo. Genomic classifiers at the time of biochemical recurrence. Presented by @dr_coops @UCSFCancer. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/bIDablDss8 @APCCC_Lugano #APCCC25 https://t.co/KphUbr7682
0
25
7
6
2K
urotoday's profile image
UroToday.com Verified account @urotoday
When to assess biology with a re-biopsy? Presentation by @mishabeltran @DanaFarber. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/3ePA6s9ARQ #APCCC25 @APCCC_Lugano
urotoday's tweet photo. When to assess biology with a re-biopsy? Presentation by @mishabeltran @DanaFarber. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/3ePA6s9ARQ #APCCC25 @APCCC_Lugano https://t.co/Z54baEs6IM
0
12
6
1
1K
urotoday's profile image
UroToday.com Verified account @urotoday
What do we expect from monitoring in metastatic #ProstateCancer? Presentation by @BertrandTOMBAL @IREC_UCLouvain. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/YHp4mSTobo @APCCC_Lugano #APCCC25
urotoday's tweet photo. What do we expect from monitoring in metastatic #ProstateCancer? Presentation by @BertrandTOMBAL @IREC_UCLouvain. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/YHp4mSTobo @APCCC_Lugano #APCCC25 https://t.co/X0bMVYioSS
0
10
5
0
846
urotoday's profile image
UroToday.com Verified account @urotoday
PSA Relapse: When Do You Need to Act? Presentation by Jochen Walz, MD @paoli_calmettes. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/0ds5XL4yRE @APCCC_Lugano #APCCC25
urotoday's tweet photo. PSA Relapse: When Do You Need to Act? Presentation by Jochen Walz, MD @paoli_calmettes. #APCCCDiagnostics25 written coverage by @RKSayyid @USC > https://t.co/0ds5XL4yRE @APCCC_Lugano #APCCC25 https://t.co/Iptzypy8Bt
0
8
3
0
768
urotoday's profile image
UroToday.com Verified account @urotoday
What do #clinicians need to know from the PSMA RLT selection PET? Presentation by Oliver Sartor, MD @MayoClinic. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/EF7tZ4cU3Y @APCCC_Lugano #APCCC25
urotoday's tweet photo. What do #clinicians need to know from the PSMA RLT selection PET? Presentation by Oliver Sartor, MD @MayoClinic. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/EF7tZ4cU3Y @APCCC_Lugano #APCCC25 https://t.co/OF1hiAUMnk
0
7
3
1
603
urotoday's profile image
UroToday.com Verified account @urotoday
What do you do with a negative scan: Treat now or later with a positive scan? Presentation by @gpalapa2 @UMich. #APCCCDiagnostics25 written coverage by @RKSayyid @USC on UroToday > https://t.co/IhQ9gFMJDX @APCCC_Lugano #APCCC25
urotoday's tweet photo. What do you do with a negative scan: Treat now or later with a positive scan? Presentation by @gpalapa2 @UMich. #APCCCDiagnostics25 written coverage by @RKSayyid @USC on UroToday > https://t.co/IhQ9gFMJDX @APCCC_Lugano #APCCC25 https://t.co/W1knHpOVFv
0
14
11
1
1K
urotoday's profile image
UroToday.com Verified account @urotoday
Biochemical Recurrence: When Do You Image? Presentation by @piet_ost @uzgent. #APCCCDiagnostics25 written coverage by @RKSayyid @USC on UroToday > https://t.co/rBaIzB523f @APCCC_Lugano #APCCC25
urotoday's tweet photo. Biochemical Recurrence: When Do You Image? Presentation by @piet_ost @uzgent. #APCCCDiagnostics25 written coverage by @RKSayyid @USC on UroToday > https://t.co/rBaIzB523f @APCCC_Lugano #APCCC25 https://t.co/dO8ZLjny6N
0
20
11
4
2K
urotoday's profile image
UroToday.com Verified account @urotoday
PCWG4 and SPARC - Including How to Define Progression on PSMA PET Imaging. Presentation by Michael Morris, MD @MSKCancerCenter. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/xxpMUW8l5H @APCCC_Lugano #APCCC25
urotoday's tweet photo. PCWG4 and SPARC - Including How to Define Progression on PSMA PET Imaging. Presentation by Michael Morris, MD @MSKCancerCenter. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/xxpMUW8l5H @APCCC_Lugano #APCCC25 https://t.co/dUdrrcPj2P
0
36
17
9
3K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Refining Prostate Cancer Screening: Balancing Detection & Overtreatment @APCCC_Lugano @OncoAlert πŸ’‘ Key insights from today’s session: βœ… PSA Testing Challenges: Overdiagnosis, false negatives, and overtreatmentβ€”how MRI pre-biopsy can improve case selection. βœ… Health Disparities: Socioeconomic deprivation linked to 14% higher mortality and 29% higher metastatic presentation in prostate cancer. βœ… Project Man-VAN 🚐: A mobile outreach model for targeted screening among ethnic minorities and underserved populations. βœ… Optimization Strategies: Reducing non-attendance rates (23%) and improving efficiency via pre-appointment digital tools. βœ… Economic Evaluation: Comparing traditional GP pathways vs. Man Van outreach, streamlining early detection. πŸ‘₯ Panel discussion with: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Refining Prostate Cancer Screening: Balancing Detection & Overtreatment @APCCC_Lugano @OncoAlert πŸ’‘ Key insights from today’s session: βœ… PSA Testing Challenges: Overdiagnosis, false negatives, and overtreatmentβ€”how MRI pre-biopsy can improve case selection. βœ… Health Disparities: Socioeconomic deprivation linked to 14% higher mortality and 29% higher metastatic presentation in prostate cancer. βœ… Project Man-VAN 🚐: A mobile outreach model for targeted screening among ethnic minorities and underserved populations. βœ… Optimization Strategies: Reducing non-attendance rates (23%) and improving efficiency via pre-appointment digital tools. βœ… Economic Evaluation: Comparing traditional GP pathways vs. Man Van outreach, streamlining early detection. πŸ‘₯ Panel discussion with: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
0
8
5
1
1K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Breaking down patient-centered PSMA PET reports! πŸ’‘ Fantastic insights from @LoebStacy on the importance of clarity in imaging reports to improve patient understanding and clinical decision-making! @APCCC_Lugano @OncoAlert πŸ”Ή Key takeaways: βœ… MRI and PSMA PET reports need clear and standardized terminology βœ… PSMA PET uptake in high-risk prostate cancer has surged (~70% by 2023) βœ… AI chatbots, including ChatGPT, show potential in improving patient comprehension βœ… Challenges persist: Only 11% of PSMA PET reports use a standardized format πŸ‘₯ Panel discussion with: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Breaking down patient-centered PSMA PET reports! πŸ’‘ Fantastic insights from @LoebStacy on the importance of clarity in imaging reports to improve patient understanding and clinical decision-making! @APCCC_Lugano @OncoAlert πŸ”Ή Key takeaways: βœ… MRI and PSMA PET reports need clear and standardized terminology βœ… PSMA PET uptake in high-risk prostate cancer has surged (~70% by 2023) βœ… AI chatbots, including ChatGPT, show potential in improving patient comprehension βœ… Challenges persist: Only 11% of PSMA PET reports use a standardized format πŸ‘₯ Panel discussion with: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
1
16
11
2
3K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Predictive and/or prognostic nomograms and biomarkers for PSMA RLT πŸ” Crystal-clear insights from @DrAGafita on optimizing PSMA radioligand therapy outcomes through predictive and prognostic tools! @APCCC_Lugano @OncoAlert πŸ“Œ Key takeaways: πŸ”Ή ctDNA as a biomarker: Lower ctDNA levels (<2%) correlate with better responses to [177Lu]Lu-PSMA-617 compared to cabazitaxel. πŸ”Ή LuPSMA nomograms can effectively stratify patients into low- vs. high-risk groups, improving treatment decision-making. πŸ”Ή SUVmean and tumor burden: Prognostic but not predictive for survival. πŸ”Ή RECIP criteria provide a structured approach for assessing treatment response. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Predictive and/or prognostic nomograms and biomarkers for PSMA RLT πŸ” Crystal-clear insights from @DrAGafita on optimizing PSMA radioligand therapy outcomes through predictive and prognostic tools! @APCCC_Lugano @OncoAlert πŸ“Œ Key takeaways: πŸ”Ή ctDNA as a biomarker: Lower ctDNA levels (<2%) correlate with better responses to [177Lu]Lu-PSMA-617 compared to cabazitaxel. πŸ”Ή LuPSMA nomograms can effectively stratify patients into low- vs. high-risk groups, improving treatment decision-making. πŸ”Ή SUVmean and tumor burden: Prognostic but not predictive for survival. πŸ”Ή RECIP criteria provide a structured approach for assessing treatment response. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
0
13
9
2
1K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ What to do in non-responding PSMA RLT patients? πŸ’‘ A highly engaging session by @drlouiseemmett on managing patients who do not respond to PSMA radioligand therapy! @APCCC_Lugano @OncoAlert πŸ”Ή Key takeaways: βœ… DNA damage increases PSMA expression – Chemotherapy agents like Daunorubicin and Mitoxantrone, as well as radiation (>6 Gy), can enhance PSMA expression, potentially improving response to PSMA-targeted therapies. βœ… Treatment intensification strategies – Ongoing trials like AcTION (NCT04597411) and PSMAcTION (NCT06780670) are exploring novel approaches to enhance PSMA RLT effectiveness. βœ… Alternative alpha-emitting therapies – Investigational agents such as Β²ΒΉΒ²Pb-PSMA and Β²Β²Β³Ra (Radium-223) offer potential strategies for patients with disease progression post-PSMA RLT. πŸ”¬ Exciting updates on new trials and strategies to overcome resistance in PSMA RLT! @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ What to do in non-responding PSMA RLT patients? πŸ’‘ A highly engaging session by @drlouiseemmett on managing patients who do not respond to PSMA radioligand therapy! @APCCC_Lugano @OncoAlert πŸ”Ή Key takeaways: βœ… DNA damage increases PSMA expression – Chemotherapy agents like Daunorubicin and Mitoxantrone, as well as radiation (>6 Gy), can enhance PSMA expression, potentially improving response to PSMA-targeted therapies. βœ… Treatment intensification strategies – Ongoing trials like AcTION (NCT04597411) and PSMAcTION (NCT06780670) are exploring novel approaches to enhance PSMA RLT effectiveness. βœ… Alternative alpha-emitting therapies – Investigational agents such as Β²ΒΉΒ²Pb-PSMA and Β²Β²Β³Ra (Radium-223) offer potential strategies for patients with disease progression post-PSMA RLT. πŸ”¬ Exciting updates on new trials and strategies to overcome resistance in PSMA RLT! @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin
0
16
7
2
1K
urotoday's profile image
UroToday.com Verified account @urotoday
New fashion blood markers for metastatic #ProstateCancer. Presentation by @Ecastromarcos. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/N0O9ik7tnu @APCCC_Lugano #APCCC25
urotoday's tweet photo. New fashion blood markers for metastatic #ProstateCancer. Presentation by @Ecastromarcos. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/N0O9ik7tnu @APCCC_Lugano #APCCC25 https://t.co/NVbBW9hTgu
0
21
9
5
2K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Key insights from PSMA PET for selecting patients for PSMA-RLT πŸ”₯ Outstanding presentation by Oliver Sartor on how to optimize patient selection for [¹⁷⁷Lu]PSMA therapy! πŸ”Ή Imaging is just one piece of the puzzle! Decision-making also considers: Disease burden (oligo vs. polymetastatic, tumor volume) Phenotype (adenocarcinoma, neuroendocrine, etc.) Lesion kinetics (response/progression speed) New lesions: Systemic vs. focal progression Image-based biomarkers (PSMA/FDG SUVmean, TTV) πŸ’‘ PSMA SUVmean & Tumor Volume (TTV) are prognostic, not predictive! Higher SUVmean correlates with better OS (TheraP trial, Hofman et al.) ctDNA fraction at baseline may predict response to PSMA-RLT πŸš€ Final take-home message: πŸ“Œ Imaging helps guide therapy, but clinical and molecular factors MUST be integrated for the best patient outcomes. @APCCC_Lugano @OncoAlert @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Key insights from PSMA PET for selecting patients for PSMA-RLT πŸ”₯ Outstanding presentation by Oliver Sartor on how to optimize patient selection for [¹⁷⁷Lu]PSMA therapy! πŸ”Ή Imaging is just one piece of the puzzle! Decision-making also considers: Disease burden (oligo vs. polymetastatic, tumor volume) Phenotype (adenocarcinoma, neuroendocrine, etc.) Lesion kinetics (response/progression speed) New lesions: Systemic vs. focal progression Image-based biomarkers (PSMA/FDG SUVmean, TTV) πŸ’‘ PSMA SUVmean & Tumor Volume (TTV) are prognostic, not predictive! Higher SUVmean correlates with better OS (TheraP trial, Hofman et al.) ctDNA fraction at baseline may predict response to PSMA-RLT πŸš€ Final take-home message: πŸ“Œ Imaging helps guide therapy, but clinical and molecular factors MUST be integrated for the best patient outcomes. @APCCC_Lugano @OncoAlert @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
1
19
11
2
2K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ The evolving role of imaging in prostate cancer management 🎀 Insightful discussion by Joe O'Sullivan on optimizing MRI & PSMA PET reporting for better clinical decision-making! @APCCC_Lugano @OncoAlert πŸ“Œ MDT’s key role in bridging imaging and oncology perspectives πŸ“Œ Avoiding unnecessary information while ensuring essential clinical insights πŸ“Œ Refining reports to aid in prognosis, treatment response & patient outcomes @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
nataliagandur's tweet photo. πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ The evolving role of imaging in prostate cancer management 🎀 Insightful discussion by Joe O'Sullivan on optimizing MRI & PSMA PET reporting for better clinical decision-making! @APCCC_Lugano @OncoAlert πŸ“Œ MDT’s key role in bridging imaging and oncology perspectives πŸ“Œ Avoiding unnecessary information while ensuring essential clinical insights πŸ“Œ Refining reports to aid in prognosis, treatment response & patient outcomes @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin Panel: @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
1
17
6
2
877
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Monitoring of patients on PSMA-radioligand therapy πŸ”₯ Masterful presentation by Andrei Iagaru on optimizing monitoring strategies for patients receiving PSMA-radioligand therapy! @APCCC_Lugano @OncoAlert πŸ” Key highlights: βœ… Cost comparison of imaging modalities: FDG-PET, PSMA-PET, and 177Lu-PSMA-617 SPECT/CT βœ… Patient selection criteria using PSMA & FDG PET/CT for therapy eligibility βœ… Post-treatment SPECT/CT: 49% of patients had management changes due to imaging findings βœ… Impact on survival: Patients with SPECT-based response had prolonged OS compared to those with progression πŸ“Š Optimizing imaging strategies is critical for patient selection and response evaluation! πŸš€ @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt πŸš€
nataliagandur's tweet photo. πŸŒŸπŸ”΅ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ Monitoring of patients on PSMA-radioligand therapy πŸ”₯ Masterful presentation by Andrei Iagaru on optimizing monitoring strategies for patients receiving PSMA-radioligand therapy! @APCCC_Lugano @OncoAlert πŸ” Key highlights: βœ… Cost comparison of imaging modalities: FDG-PET, PSMA-PET, and 177Lu-PSMA-617 SPECT/CT βœ… Patient selection criteria using PSMA & FDG PET/CT for therapy eligibility βœ… Post-treatment SPECT/CT: 49% of patients had management changes due to imaging findings βœ… Impact on survival: Patients with SPECT-based response had prolonged OS compared to those with progression πŸ“Š Optimizing imaging strategies is critical for patient selection and response evaluation! πŸš€ @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt πŸš€
0
13
9
2
1K
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ When to assess biology with ctDNA? πŸ” Crystal-clear explanation by @ResearchWyatt on the role of ctDNA in dynamic tumor assessment and treatment decisions! @APCCC_Lugano @OncoAlert πŸ’‘ Key takeaways: βœ… Early ctDNA clearance predicts better outcomes compared to PSA alone. βœ… ctDNA as a response biomarker is being integrated into RECIST guidelines. βœ… Challenges remain: standardization, biological confounders, and optimal timing. βœ… Next steps: refining thresholds, simplifying assays, and designing trials to validate interventions. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
nataliagandur's tweet photo. πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ When to assess biology with ctDNA? πŸ” Crystal-clear explanation by @ResearchWyatt on the role of ctDNA in dynamic tumor assessment and treatment decisions! @APCCC_Lugano @OncoAlert πŸ’‘ Key takeaways: βœ… Early ctDNA clearance predicts better outcomes compared to PSA alone. βœ… ctDNA as a response biomarker is being integrated into RECIST guidelines. βœ… Challenges remain: standardization, biological confounders, and optimal timing. βœ… Next steps: refining thresholds, simplifying assays, and designing trials to validate interventions. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
0
12
5
1
816
nataliagandur's profile image
Dra. MarΓ­a Natalia Gandur Quiroga Verified account @nataliagandur
Β· Ciudad AutΓ³noma de Buenos Aires
πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ When to assess biology with ctDNA? πŸ” Crystal-clear explanation by @ResearchWyatt on the role of ctDNA in dynamic tumor assessment and treatment decisions! @APCCC_Lugano @OncoAlert πŸ’‘ Key takeaways: βœ… Early ctDNA clearance predicts better outcomes compared to PSA alone. βœ… ctDNA as a response biomarker is being integrated into RECIST guidelines. βœ… Challenges remain: standardization, biological confounders, and optimal timing. βœ… Next steps: refining thresholds, simplifying assays, and designing trials to validate interventions. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
nataliagandur's tweet photo. πŸŒŸπŸ”΄ LIVE from #APCCC25! #APCCCDiagnostics25 πŸ“’ When to assess biology with ctDNA? πŸ” Crystal-clear explanation by @ResearchWyatt on the role of ctDNA in dynamic tumor assessment and treatment decisions! @APCCC_Lugano @OncoAlert πŸ’‘ Key takeaways: βœ… Early ctDNA clearance predicts better outcomes compared to PSA alone. βœ… ctDNA as a response biomarker is being integrated into RECIST guidelines. βœ… Challenges remain: standardization, biological confounders, and optimal timing. βœ… Next steps: refining thresholds, simplifying assays, and designing trials to validate interventions. @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt
0
17
7
1
1K

Last Seen Hashtags on Sotwe

ζ£‰θ’œ
ipcam()+filter:native_video
Seen from Netherlands
omegle
Seen from Australia
eskişehirmasaj
Seen from Turkey
leakedvideoviral
Seen from Norway
britishtaxpayers
Seen from United States
facialwhilefucked
Seen from United Kingdom
上桷鸟洞
Ekaterina_Killer
Seen from Latvia
snapchat()****
Seen from Turkey

Trends for you

1
#DreaminaMadeItViral
Under 10K tweets
2
#OlandriaxOffWhite
Under 10K tweets
3
Halo
Under 10K tweets
4
Opus 5.5
Under 10K tweets
5
Good Wednesday
Under 10K tweets
6
Activision
Under 10K tweets
7
Trump TV
Under 10K tweets
8
Dart
Under 10K tweets
9
#dwts
Under 10K tweets
10
Giants
Under 10K tweets

Most Popular Users

elonmusk's profile image
1
Elon Musk Verified account
@elonmusk
241.7M followers
barackobama's profile image
2
Barack Obama Verified account
@barackobama
119M followers
cristiano's profile image
3
Cristiano Ronaldo Verified account
@cristiano
114.4M followers
realdonaldtrump's profile image
4
Donald J. Trump Verified account
@realdonaldtrump
111.9M followers
narendramodi's profile image
5
Narendra Modi Verified account
@narendramodi
107.2M followers
rihanna's profile image
6
Rihanna Verified account
@rihanna
98.7M followers
nasa's profile image
7
NASA Verified account
@nasa
92.4M followers
justinbieber's profile image
8
Justin Bieber Verified account
@justinbieber
91.8M followers
katyperry's profile image
9
KATY PERRY Verified account
@katyperry
90M followers
taylorswift13's profile image
10
Taylor Swift
@taylorswift13
83.9M followers
ladygaga's profile image
11
Lady Gaga Verified account
@ladygaga
75.4M followers
imvkohli's profile image
12
Virat Kohli Verified account
@imvkohli
73.3M followers
kimkardashian's profile image
13
Kim Kardashian Verified account
@kimkardashian
70.9M followers
youtube's profile image
14
YouTube Verified account
@youtube
68.8M followers
neymarjr's profile image
15
Neymar Jr Verified account
@neymarjr
66.3M followers
billgates's profile image
16
Bill Gates Verified account
@billgates
65.1M followers
selenagomez's profile image
17
Selena Gomez Verified account
@selenagomez
63M followers
theellenshow's profile image
18
The Ellen Show
@theellenshow
62.3M followers
cnn's profile image
19
CNN Verified account
@cnn
61.8M followers
x's profile image
20
X Verified account
@x
60.7M followers